RxDoctor Payments Data

Fritz Lemoine, MD

Internal Medicine · Naples, FLNPI 1639251309

Payments from drug & device makers

$583in general payments, 2019–2025

Across 26 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$251
  • AstraZeneca$100
  • Pfizer$82
  • GSK$54
  • Amarin Pharma, Inc.$29
  • Boehringer Ingelheim$28
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$54393%
  • Education$407%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$583 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$11,303
Medicare patients
72
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$17,899
SynthroidLevothyroxine Sodium15$964
Duloxetine Hcl24$830
Olmesartan Medoxomil29$752
Rosuvastatin Calcium46$555
Omeprazole13$453
Metoprolol Succinate18$447
Rabeprazole Sodium12$444
Losartan Potassium13$374
Montelukast Sodium17$310
Levothyroxine Sodium12$259
Pantoprazole Sodium16$242
Amlodipine Besylate24$191
Zolpidem Tartrate19$173
Methylprednisolone15$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$17,89912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →